Tacrolimus is an immunosuppressive drug that is given orally or intravenously to patients who have had a kidney, liver, heart, or other organ transplant.
Normally, a person’s immune system would recognise the new organ as foreign and begin to attack it. Tacrolimus limits this response and helps to prevent organ rejection by inhibiting the activation of T-lymphocytes.
Randox Toxicology have developed a new tacrolimus single-plex biochip assay which is available on the Evidence MultiSTAT, to aid in the monitoring of tacrolimus at the location of treatment.
Benefits
Broad Assay Range
Broad assay range covers a narrow therapeutic window for monitoring multiple organ transplant levels.
Real-time Analysis
Real-time analysis of peak and trough levels improves patient outcomes and
reduces the risk of rejections or toxicity.
No Batch Processing
No batch processing of samples provides flexibility in testing schedules.
Cartridge-based System
Cartridge-based system ensures tests remain stable and reliable over extended periods.
Rapid Analysis
Rapid analysis allows timely therapeutic decisions and adjustments in immunosuppressive therapy
Simplified Testing Process
Simplified testing process with minimal sample preparation and user-friendly interface, reduces the need for specialised training.
